Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine 5 mg plus standard triple antiemetic regimen for chemotherapy-induced nausea and vomiting in breast cancer
ChiCTR2600118281Phase 3Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of olanzapine in chemotherapy-induced nausea and vomiting (CINV) and breast cancer (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Complete remission rate (overall, 0–120 h). Started Feb 2026; status: recruiting.
02
Drugs
olanzapine
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)breast cancer
Beyond the preview
Go deeper on ChiCTR2600118281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118281.